Mapping human microbiome drug metabolism by gut bacteria and their genes

Nature

Volumn 570, Issue 7762, 2019, Pages 462-467

  Zimmermann, Michael ^a   Zimmermann Kogadeeva, Maria ^a   Wegmann, Rebekka ^a,b   Goodman, Andrew L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DILTIAZEM; DRUG METABOLITE; DRUG;

BACTERIUM; DRUG DEVELOPMENT; ENZYME; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENOMICS; METABOLISM; MICROBIAL ACTIVITY; MICROBIAL COMMUNITY; MICROORGANISM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; CONTROLLED STUDY; DRUG ELIMINATION; DRUG METABOLISM; DRUG RESEARCH; GENETIC ANALYSIS; GENOMICS; HIGH THROUGHPUT SEQUENCING; HUMAN; IN VIVO STUDY; INTESTINE FLORA; MASS SPECTROMETRY; MICROBIAL GENE; MICROBIOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; ANIMAL; BACTERIAL GENOME; BACTERIUM; BACTEROIDES THETAIOTAOMICRON; CLASSIFICATION; ENZYME SPECIFICITY; ENZYMOLOGY; FEMALE; GENETICS; GERMFREE ANIMAL; MALE; METABOLISM; PHYSIOLOGY;

BACTERIA (MICROORGANISMS); MUS;

ANIMALS; BACTERIA; BACTEROIDES THETAIOTAOMICRON; DILTIAZEM; FEMALE; GASTROINTESTINAL MICROBIOME; GENOME, BACTERIAL; GERM-FREE LIFE; HUMANS; MALE; MICE; PHARMACEUTICAL PREPARATIONS; SUBSTRATE SPECIFICITY;

EID: 85067882185     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/s41586-019-1291-3     Document Type: Article

References (41)

1. Obach, R. S. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy. Pharmacol. Rev. 65, 578–640 (2013).
2. Sousa, T. et al. On the colonic bacterial metabolism of azo-bonded prodrugs of 5-aminosalicylic acid. J. Pharm. Sci. 103, 3171–3175 (2014).
3. Haiser, H. J. et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341, 295–298 (2013).
4. Okuda, H., Ogura, K., Kato, A., Takubo, H. & Watabe, T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J. Pharmacol. Exp. Ther. 287, 791–799 (1998).
5. Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R. & Goodman, A. L. Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science 363, eaat9931 (2019).
6. Wallace, B. D. et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831–835 (2010).
7. Klatt, N. R. et al. Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science 356, 938–945 (2017).
8. Aziz, R. K., Hegazy, S. M., Yasser, R., Rizkallah, M. R. & ElRakaiby, M. T. Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug–microbiome interactions. Expert Opin. Drug Metab. Toxicol. 14, 1043–1055 (2018).
9. Goodman, A. L. et al. Identifying genetic determinants needed to establish a human gut symbiont in its habitat. Cell Host Microbe 6, 279–289 (2009).
10. Wilson, I. D. & Nicholson, J. K. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl. Res. 179, 204–222 (2017).
11. Winter, J. et al. Mode of action of steroid desmolase and reductases synthesized by Clostridium “scindens” (formerly Clostridium strain 19). J. Lipid Res. 25, 1124–1131 (1984).
12. Morris, G. N., Winter, J., Cato, E. P., Ritchie, A. E. & Bokkenheuser, V. D. Clostridium scindens sp. nov., a human intestinal bacterium with desmolytic activity on corticoids. Int. J. Syst. Evol. Microbiol. 35, 478–481 (1985).
13. Ridlon, J. M. et al. Clostridium scindens: a human gut microbe with a high potential to convert glucocorticoids into androgens. J. Lipid Res. 54, 2437–2449 (2013).
14. Boyd, R. A. et al. The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. Clin. Pharmacol. Ther. 46, 408–419 (1989).
15. Molden, E., Åsberg, A. & Christensen, H. Desacetyl-diltiazem displays severalfold higher affinity to CYP2D6 compared with CYP3A4. Drug Metab. Dispos. 30, 1–3 (2002).
16. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
17. Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623–628 (2018).
18. Wu, H. et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23, 850–858 (2017).
19. Clayton, T. A., Baker, D., Lindon, J. C., Everett, J. R. & Nicholson, J. K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl Acad. Sci. USA 106, 14728–14733 (2009).
20. Björkholm, B. et al. Intestinal microbiota regulate xenobiotic metabolism in the liver. PLoS ONE 4, e6958 (2009).
21. Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074–D1082 (2018).
22. Goodman, A. L. et al. Extensive personal human gut microbiota culture collections characterized and manipulated in gnotobiotic mice. Proc. Natl Acad. Sci. USA 108, 6252–6257 (2011).
23. Holdeman, L. V., Moore, W. E. C. & Cato, E. P. Anaerobe Laboratory Manual (Virginia Polytechnic Institute and State Univ., 1977).
24. Forsberg, K. J. et al. The shared antibiotic resistome of soil bacteria and human pathogens. Science 337, 1107–1111 (2012).
25. Goodman, A. L., Wu, M. & Gordon, J. I. Identifying microbial fitness determinants by insertion sequencing using genome-wide transposon mutant libraries. Nat. Protoc. 6, 1969–1980 (2011).
26. Koropatkin, N. M., Martens, E. C., Gordon, J. I. & Smith, T. J. Starch catabolism by a prominent human gut symbiont is directed by the recognition of amylose helices. Structure 16, 1105–1115 (2008).
27. Warrens, A. N., Jones, M. D. & Lechler, R. I. Splicing by overlap extension by PCR using asymmetric amplification: an improved technique for the generation of hybrid proteins of immunological interest. Gene 186, 29–35 (1997).
28. Whitaker, W. R., Shepherd, E. S. & Sonnenburg, J. L. Tunable expression tools enable single-cell strain distinction in the gut microbiome. Cell 169, 538–546.e12 (2017).
29. Petersen, T. N., Brunak, S., von Heijne, G. & Nielsen, H. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat. Methods 8, 785–786 (2011).
30. Lim, B., Zimmermann, M., Barry, N. A. & Goodman, A. L. Engineered regulatory systems modulate gene expression of human commensals in the gut. Cell 169, 547–558.e15 (2017).
31. Cullen, T. W. et al. Antimicrobial peptide resistance mediates resilience of prominent gut commensals during inflammation. Science 347, 170–175 (2015).
32. Camacho, C. et al. BLAST+: architecture and applications. BMC Bioinformatics 10, 421 (2009).
33. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
34. McIver, L. J. et al. bioBakery: a meta’omic analysis environment. Bioinformatics 34, 1235–1237 (2018).
35. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).
36. Truong, D. T. et al. MetaPhlAn2 for enhanced metagenomic taxonomic profiling. Nat. Methods 12, 902–903 (2015).
37. Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335–336 (2010).
38. Kaminski, J. et al. High-specificity targeted functional profiling in microbial communities with ShortBRED. PLOS Comput. Biol. 11, e1004557 (2015).
39. Suzek, B. E., Wang, Y., Huang, H., McGarvey, P. B. & Wu, C. H. UniRef clusters: a comprehensive and scalable alternative for improving sequence similarity searches. Bioinformatics 31, 926–932 (2015).
40. Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26, 2460–2461 (2010).
41. Yeung, P. K. et al. Pharmacokinetics and metabolism of diltiazem in healthy males and females following a single oral dose. Eur. J. Drug Metab. Pharmacokinet. 18, 199–206 (1993).